ZNF638 and glioblastoma: Given these findings, we sought to understand the role of ZNF638 in predicting long-term responses to immunotherapy in GBM using genomic and transcriptomic profiling of patients who received ICI (αPD-1, nivolumab, or pembrolizumab).